Akeso, Inc.

9926

KYG0146B1032

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. Other stock markets 01:38:09 13/02/2026 pm IST			5-day change	1st Jan Change
105.30 ^HKD	+1.54%		+4.36%	-6.81%

11/02	Akeso, Inc.'s IL-4Ra/ST2 Bispecific Antibody Cleared for Seven Phase II Studies in China Spanning Respiratory and Autoimmune Indications	CI
06/02	Akeso, Inc. Receives Fifth Breakthrough Therapy Designation from NMPA for Ivonescimab in First-Line Treatment of Advanced Biliary Tract Cancer	CI

UBS Adjusts Akeso’s Price Target to HK$26.68 From HK$29.60, Keeps at Buy

Published on 06/08/2022 at 02:23 pm IST - Modified on 06/08/2022 at 02:24 pm IST

MT Newswires

Latest news about Akeso, Inc.

11/02	Akeso, Inc.'s IL-4Ra/ST2 Bispecific Antibody Cleared for Seven Phase II Studies in China Spanning Respiratory and Autoimmune Indications	CI
06/02	Akeso, Inc. Receives Fifth Breakthrough Therapy Designation from NMPA for Ivonescimab in First-Line Treatment of Advanced Biliary Tract Cancer	CI
03/02	Akeso granted exclusive commercialization rights for ebronucimab injection to Jumpcan Pharmaceutical	RE
03/02	Akeso Grants Commercialization Rights for Hypercholesterolemia Drug to Hubei Jumpcan Pharmaceutical Unit	MT
29/01	Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy	CI
19/01	Akeso, Inc. Announces NMPA Acceptance of Second NDA for Gumokimab (IL-17A Inhibitor) in Active Ankylosing Spondylitis	CI
14/01	Akeso, Inc. Announces Presentation of Real-World Study At the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium	CI
13/01	Summit Therapeutics Inc. Announces Submission of Biologics License Application to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC	CI
07/01	Akeso, Inc. Announces the National Medical Products Administration Approves Significant Label Update in China for its Internally Develop, PD-1/VEGF Bispecific Antibody, ivonescimab	CI
12/12	Cadonilimab (PD-1/CTLA-4) Receives FDA Clearance for Global Phase III First-Line Gastric Cancer Trial Versus Nivolumab	CI
11/12	Akeso, Inc. Announces Updated Efficacy Data of Ivonescimab Combined with Chemotherapy as First-Line Treatment for TNBC Presented atESMO IO 2025	CI
09/12	Akeso, Inc. Announces Phase II Data of Cadonilimab Regimen as Neoadjuvant Therapy for Resectable Gastric Cancer Presented at ESMO Asia Congress	CI
09/12	Akeso, Inc. Announces Significant Improvement in Quality of Life Reported in Updated HARMONi-6 Data for Ivonescimab at ESMO Asia	CI
17/11	Akeso, Inc.'s Bispecific Antibody Targeting Aß and BBB-Expressed Receptor Approved for Alzheimer's Disease Clinical Trials in China	CI
10/11	Akeso announces first patient dosed in Phase I trial of personalized mRNA vaccine AK154 as monotherapy or in combination with Cadonilimab or Ivonescimab	RE

Akeso Inc is an investment holding company mainly engaged in the research and development, production and commercialization of biopharmaceutical products. The Company is committed to the research, development, manufacturing and commercialization of innovative antibody drugs that are affordable to patients worldwide. The Company's products mainly include cadonilimab (PD-1/CTLA-4), Ivonescimab (AK112, PD-1/VEGF), ANNIKO (penpulimab, PD-1), Ebronucimab (AK102, PCSK9) and ebdarokimab (AK101, IL-12/IL-23). The Company's products are principally used to treat tumors, autoimmune diseases, metabolic diseases, as well as neurodegenerative diseases. The Company principally conducts its businesses in Mainland China, the United States and other markets.

Employees

3,529

Sector

Biotechnology & Medical Research

Calendar

01/04 - Q4 2025 Earnings Release (Projected)

More about the company